The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study)

BACKGROUND: Tiotropium + olodaterol has demonstrated improvements beyond lung function benefits in a large Phase III clinical program as a once-daily maintenance treatment for COPD and may be a potential option for the initiation of maintenance treatment in COPD. Despite guideline recommendations th...

Descripción completa

Detalles Bibliográficos
Autores principales: Beeh, Kai-Michael, Derom, Eric, Echave-Sustaeta, José, Grönke, Lars, Hamilton, Alan, Zhai, Dongmei, Bjermer, Leif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745834/
https://www.ncbi.nlm.nih.gov/pubmed/26893551
http://dx.doi.org/10.2147/COPD.S95055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745834/
https://www.ncbi.nlm.nih.gov/pubmed/26893551
http://dx.doi.org/10.2147/COPD.S95055

Ejemplares similares